Medical Health & Life Science Research News

New report examines the global meningioma pipeline therapeutics and drug profiles

Meningioma pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Learn details of the Pipeline Meningioma tumor Therapeutics Development Review H1 2017

- Agency -.

Meningioma Pipeline Review H1 2017 report provides comprehensive information on the therapeutics under development for Meningioma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

Additionally, the report provides an overview of key players involved in therapeutic development for Meningioma and features dormant and discontinued projects. Meningioma is cancer that starts in the endometrium, the lining of the uterus (womb).

- Agency -.

Meningioma is the most common type of uterine cancer.

Report: www.reportsnreports.com/contacts/.aspx?name=1057906

Description of Report:

Meningioma Pipeline Review H1 2017 reviews of key players involved in therapeutic development for Meningioma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Phase 0 stages are 5, 2 and 1 respectively.

Similarly, the Universities portfolio in Preclinical stages comprises 1 molecule, respectively. Report features investigational drugs from across globe covering therapy areas and indications.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The report provides a snapshot of the global therapeutic landscape of Meningioma.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Key Companies Analyzed In Report:

Arno Therapeutics Inc, AstraZeneca Plc, Boehringer Ingelheim GmbH, GlaxoSmithKline Plc, Novartis AG, Pharma Mar SA, Progenics Pharmaceuticals Inc.

Meningioma Pipeline Drug Discussed:

afatinib dimaleate, AR-42, Edotreotide Labeled Yttrium 90, GSK-2256098, HXR-9, pasireotide ER, selumetinib sulfate, trabectedin, vistusertib

Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Meningioma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage

Report: www.reportsnreports.com/contacts/.aspx?name=1057906

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies. Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Identify and understand important and diverse types of therapeutics under development for Meningioma. Identify potential new clients or partners in the target demographic.

Develop strategic initiatives by understanding the focus areas of leading companies. Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics.

Devise corrective measures for pipeline projects by understanding Meningioma pipeline depth and focus of Indication therapeutics. Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Major Table OF Content

  • Number of Products under Development for Meningioma, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Meningioma - Pipeline by Arno Therapeutics Inc, H1 2017
  • Meningioma - Pipeline by AstraZeneca Plc, H1 2017
  • Meningioma - Pipeline by Boehringer Ingelheim GmbH, H1 2017
  • Meningioma - Pipeline by GlaxoSmithKline Plc, H1 2017
  • Meningioma - Pipeline by Novartis AG, H1 2017
  • Meningioma - Pipeline by Pharma Mar SA, H1 2017
  • Meningioma - Pipeline by Progenics Pharmaceuticals Inc, H1 2017
  • Meningioma - Dormant Projects, H1 2017
  • Meningioma - Discontinued Products, H1 2017

Access Report Complete Pdf Report of 71 Pages with 21 Tables and 10 Figures: www.reportsnreports.com/.aspx?name=1057906

 

News From

ReportsnReports - Industry Trends & ForecastsReportsnReports
Category: Market Research Publishers and RetailersCompany profile: ReportsnReports.com provides market research reports to industries, individuals and organizations with an objective of helping them in their decision-making process. Our library of 400,000+ industry & country research reports covers 5000+ micro markets.